TY - JOUR
T1 - Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: A study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover
AU - Pedersen, Susanne Juhl
AU - Sørensen, Inge Juul
AU - Lambert, Robert G W
AU - Hermann, Kay-Geert A
AU - Garnero, Patrick
AU - Johansen, Julia Sidenius
AU - Madsen, Ole Rintek
AU - Hansen, Annette
AU - Hansen, Michael Sejer
AU - Thamsborg, Gorm
AU - Andersen, Lis Smedegaard
AU - Majgaard, Ole
AU - Loft, Anne Gitte
AU - Erlendsson, Jon
AU - Asmussen, Karsten H
AU - Jurik, Anne Grethe
AU - Møller, Jakob
AU - Hasselquist, Maria
AU - Mikkelsen, Dorrit
AU - Østergaard, Mikkel
N1 - Copyright © 2011 by the American College of Rheumatology.
PY - 2011
Y1 - 2011
N2 - To investigate the relationship of circulating biomarkers of inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], and YKL-40), angiogenesis (vascular endothelial growth factor), cartilage turnover (C-terminal crosslinking telopeptide of type II collagen [CTX-II], total aggrecan, matrix metalloproteinase 3 [MMP-3], and cartilage oligomeric matrix protein [COMP]), and bone turnover (CTX-I and osteocalcin) to inflammation on magnetic resonance imaging (MRI) and radiographic progression in patients with axial spondylarthritis (SpA) beginning tumor necrosis factor α (TNFα) inhibitor therapy.
AB - To investigate the relationship of circulating biomarkers of inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], and YKL-40), angiogenesis (vascular endothelial growth factor), cartilage turnover (C-terminal crosslinking telopeptide of type II collagen [CTX-II], total aggrecan, matrix metalloproteinase 3 [MMP-3], and cartilage oligomeric matrix protein [COMP]), and bone turnover (CTX-I and osteocalcin) to inflammation on magnetic resonance imaging (MRI) and radiographic progression in patients with axial spondylarthritis (SpA) beginning tumor necrosis factor α (TNFα) inhibitor therapy.
U2 - 10.1002/art.30627
DO - 10.1002/art.30627
M3 - Journal article
C2 - 22127697
SN - 0004-3591
VL - 63
SP - 3789
EP - 3800
JO - Arthritis & Rheumatism
JF - Arthritis & Rheumatism
IS - 12
ER -